The European Commission has announced that it has approved an agreement that allows European Union (EU) member states to purchase up to 200 million doses of Novavax’s Covid-19 vaccine, once the European Medicines Agency ( EMA) deems it safe and efficient to use.
In a statement on Wednesday, the Commission said that thanks to the deal with the US pharmaceutical company, EU countries will be able to purchase 100 million doses of Novavax vaccine, with the possibility of purchasing an additional 100 million over the course of 2021, 2022 and 2023, reports the Xinhua news agency.
European Commission President Ursula von der Leyen hailed the deal as further strengthening the bloc’s “large vaccine portfolio”.
The EU has already signed contracts with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNTech-Pfizer, CureVac, Moderna and concluded exploratory talks with Valneva.
The contracts previously concluded have made it possible to secure a portfolio of up to 4.4 billion doses.
Wealthy Western nations have been accused of accumulating far more doses than their citizens need.
The Washington Post previously estimated that the United States has bought coronavirus vaccines three times the amount needed, while many developing countries are still struggling to get a single dose.
The World Health Organization (WHO) on Wednesday called on rich countries to suspend the Covid-19 booster vaccine distribution plan, citing the inequality of vaccines around the world.
“We need an urgent reversal of the majority of vaccines intended for high-income countries, the majority for low-income countries,” WHO Director-General Tedros Adhanom Ghebreyesus said at a briefing.
(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)